Pertussis (Whooping Cough) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Pertussis (Whooping Cough) - Pipeline Review, H1 2018’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)

The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pertussis (Whooping Cough) therapeutics and enlists all their major and minor projects

The report assesses Pertussis (Whooping Cough) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

BlueWillow Biologics

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co ...

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

BlueWillow Biologics

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

DBV Technologies SA

GC Pharma

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

Panacea Biotec Ltd

Sanofi

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Synthetic Biologics Inc

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pertussis (Whooping Cough) – Overview

Pertussis (Whooping Cough) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pertussis (Whooping Cough) – Overview

Pertussis (Whooping Cough) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pertussis (Whooping Cough) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pertussis (Whooping Cough) – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

BlueWillow Biologics

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

DBV Technologies SA

GC Pharma

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

Panacea Biotec Ltd

Sanofi

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Synthetic Biologics Inc

Wockhardt Ltd

Pertussis (Whooping Cough) – Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular)) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1004 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bladder cancer + pertussis + tuberculosis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTcP vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GamLPV – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3111A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis (acellular) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis (acellular) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pertussis (Whooping Cough) – Dormant Projects

Pertussis (Whooping Cough) – Discontinued Products

Pertussis (Whooping Cough) – Product Development Milestones

Featured News & Press Releases

Aug 29, 2017: The HUG Completes the PertADO Trial Evaluating Pertagen, a New Recombinant Pertussis Vaccine, in Adolescents in Switzerland

Jul 05, 2017: ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study

Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)

Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine – Hexaxim

Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine– Hexaxim

Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting

Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough

Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pertussis (Whooping Cough) – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Bharat Biotech Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Biological E Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by BlueWillow Biologics, H1 2018

Pertussis (Whooping Cough) – Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Cadila Healthcare Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by DBV Technologies SA, H1 2018

Pertussis (Whooping Cough) – Pipeline by GC Pharma, H1 2018

Pertussis (Whooping Cough) – Pipeline by GlaxoSmithKline Plc, H1 2018

Pertussis (Whooping Cough) – Pipeline by Indian Immunologicals Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Kaketsuken, H1 2018

Pertussis (Whooping Cough) – Pipeline by LG Chem Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Panacea Biotec Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Sanofi, H1 2018

Pertussis (Whooping Cough) – Pipeline by Sanofi Pasteur SA, H1 2018

Pertussis (Whooping Cough) – Pipeline by Serum Institute of India Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Shantha Biotechnics Pvt Ltd, H1 2018

Pertussis (Whooping Cough) – Pipeline by Synthetic Biologics Inc, H1 2018

Pertussis (Whooping Cough) – Pipeline by Wockhardt Ltd, H1 2018

Pertussis (Whooping Cough) – Dormant Projects, H1 2018

Pertussis (Whooping Cough) – Dormant Projects, H1 2018 (Contd..1), H1 2018

Pertussis (Whooping Cough) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports